Korean firm Arigene to pay $81 million for Trimeris
This article was originally published in Scrip
Executive Summary
The US company Trimeris, which developed Fuzeon (enfuvirtide), the first fusion inhibitor approved for the treatment of HIV, has entered an agreement to be acquired for around $81 million by South Korean firm Arigene, which is looking to move into biotechnology.